Our museum and library is closed today in celebration of Juneteenth.

Distillations podcast

Deep Dives into Science Stories, Both Serious and Eccentric
September 21, 2021 Health & Medicine

What Causes Alzheimer’s?

Vox’s ‘Unexplainable’ podcast interviews ‘Distillations’ about how Alzheimer’s research has stubbornly focused on a single theory for decades.

Vox's Unexplainable podcast logo: the word Unexplainable on a grid of black squares and white lines.

The human brain is mysterious and complicated. So much so, one might be tempted to argue, it only makes sense we still don’t have a cure for Alzheimer’s disease, despite decades of research. But this isn’t the whole story. We’ve partnered with Vox’s Unexplainable science podcast to talk about how Alzheimer’s researchers have been stubbornly pursuing a single theory for decades. The Amyloid Hypothesis is the reigning champ amongst pharmaceutical companies and scientific scholars and it has pushed all other theories to the wayside. Over the years scientists have developed many drugs based on the Amyloid Hypothesis but the the clinical trials keep failing. Now some researchers are starting to wonder if the reason we still don’t have a cure is that we’ve put all of our scientific eggs in one faulty basket.

You can hear more about Alzheimer’s disease on The Alzheimer’s Copernicus Problem, a two-part Distillations podcast episode that Vox used as a resource for its show.



Hosts: Alexis Pedrick and Elisabeth Berry Drago
Senior Producer: Mariel Carr
Producer: Rigoberto Hernandez
Audio Engineer: Jonathan Pfeffer


This episode was produced by Rigo Hernandez, Alexis Pedrick, Dylan Scott, and Byrd Pinkerton. It was edited by Noam Hassenfeld and Brian Resnick, with help from Meradith Hoddinott and Mandy Nguyen, who also did the fact checking. Noam Hassenfeld wrote the music, Cristian Ayala did the mixing and sound design. 

Image courtesy of Vox Media Group.


Alexis: Hello and welcome to Distillations. I’m Alexis Pedrick.

Lisa: and I’m Lisa Barry Drago. Last June the FDA approved a drug to treat Alzheimer’s, the devastating type of dementia that affects more than 6 million Americans.

Alexis: News of this drug, which was the first new one in 18 years, should have been caused for celebration. But it wasn’t, not exactly.

PBS NEWS HOUR: The FDA’s approval of a new Alzheimer’s drug today followed months of debate within the medical community about the agency’s procedures, which, as Amna Nevaz reports, the announcement has done little to quiet.

CNBC: On its face you’d think the first Alzheimer’s drug approved in 18 years would be nothing but good news that everyone would be happy about, but this is in fact a tremendous controversy in the scientific and medical world, and it’s all because of the data behind Biogen’s Alzheimer’s drug.   

Lisa: Our friends at the Vox science podcast Unexplainable wanted to understand how this drug could have been approved on such shaky grounds, so they turned to us!

Alexis: That’s right–we are Alzheimer’s experts. At least we are now, because two years ago we dove deep into this subject for a two-part podcast called the Alzheimer’s Copernicus Problem.

Sharon Begley: Why are all of these, you know, very well-respected very highly capitalized companies continuing to bring forth compounds into phase one trials, phase two, and then the very, very expensive phase threes, and they simply don’t work. I mean, how much bad luck can there be? And that’s when a number of researchers both central to the field themselves and also, uh, some on the periphery by which I mean they’re neurologists, but they don’t necessarily focus on Alzheimer’s, they said in Alzheimer’s disease more than any disorder that they’re aware of, a particular hypothesis has just dominated the field in a way that they had never seen before.

Alexis: And I had the pleasure of talking with Unexplainable host Noam Hassenfeld about the failures of Alzheimer’s research, and how scientists are humans and they want easy answers just like the rest of us…onto the episode:

NOAM HASSENFELD (HOST): More than 6 million Americans are currently living with Alzheimer’s disease. It’s a terrible, neurodegenerative form of dementia, that destroys the memory, and physically deforms the brain. As the population ages, this 6 million number will only increase. So scientists have been searching for an Alzheimer’s cure for decades. But they haven’t had much luck. 

<TAPE> ALEXIS PEDRICK (HOST, DISTILLATIONS PODCAST): You know, my father died of dementia and it’s really hard. But I also… I expect for science to be having a hard time with this. 

NOAM: This is Alexis Pedrick. She’s the host of the science history podcast, Distillations. 

<TAPE> ALEXIS: You know, the brain is complex. And if all these researchers are going back and forth over different theories, that makes sense to me.

NOAM: That’s what Alexis told her producer Rigo Hernandez, when he pitched her a story on Alzheimer’s. 

<TAPE> ALEXIS: And Rigo sort of stopped me and said, “Well, but we’re not going back and forth over all these different theories. We’ve been pursuing one theory, the same theory for about 30 years.” [laughs] And that kind of stopped us in our tracks. I mean, it blew our minds. This idea that we’ve kind of been excluding all other sort of research and ideas and treating science like it’s this zero sum game.


NOAM: I’m Noam Hassenfeld, and this week on Unexplainable, how we got stuck in this zero sum game, which has led to an even trickier question:

<TAPE> ALEXIS: What does that mean for a disease like Alzheimer’s? 

NOAM: So Alexis, before we get to the different hypotheses of what might be causing Alzheimer’s, do we have any understanding of how it actually works in the brain?

ALEXIS: A little bit. I mean we don’t—we don’t know a lot. So back in 1906, there was this guy, Dr. Alois Alzheimer, and he observed this patient of his that had delusions and memory loss. And after he did this autopsy, he stained the tissues of her brain and he found all these sticky plaques and tangles. And that’s kind of what we consider to be the hallmark of the disease now.


ALEXIS: So, you know, we know what it looks like. We know what it  does, but we don’t know exactly what causes it. 

NOAM: Ok, so this is, I assume, where we get to the different theories right?

ALEXIS: Right exactly.

NOAM: So what’s the one hypothesis that’s been dominating Alzheimer’s research?

ALEXIS: So it’s called the amyloid hypothesis because it focuses on this type of brain trash called the beta amyloid…

NOAM: Brain trash? 

ALEXIS: Yeah [laugh] It’s a technical term, brain trash. [laughs] 

NOAM: Sure, yeah, sounds technical

ALEXIS: So basically, your brain’s a really busy place. 

ALEXIS: It’s got neurons that are constantly firing off and doing things. And these neurons and all the other cells in there, they produce trash, like the beta amyloid protein. So in a normal brain, all that gets flushed out it’s fine. No problem. But the amyloid hypothesis says that when the beta amyloid doesn’t get flushed out, you get these sticky plaques that Alois Alzheimer observed. And that’s when you have the hallmarks of Alzheimer’s. The memory loss. The cognitive impairment. Everything he was seeing that patient do. 

NOAM: So the idea in this hypothesis would be to get rid of the beta amyloid proteins, the brain trash, that would help Alzheimer’s get better?

ALEXIS: Yeah. If we can prevent it from building up and causing all these problems, all systems go. 


NOAM: This is still just a hypothesis though, right? How did it take over all of Alzheimer’s research?

ALEXIS: So, we talked to this guy named John Hardy, who’s a geneticist in the UK. And he’s out, he’s doing his research in the early 1990s, and he found that plaques could form when there was a mutation in the protein that produces beta amyloids. And that’s what really kicked things into high gear. 

<TAPE> JOHN HARDY (GENETICIST): Many, many other hypotheses had been suggested. And when we found the mutation, I felt this was the referee. And so the referee called it for the amyloid hypothesis. That’s how I felt it. And I think that’s how everybody else felt it.  


ALEXIS: The way he explained it made a lot of sense. If you have this mutation that causes you to have a lot more beta amyloid, all that buildup reaches critical mass, it causes inflammation, it gives you these tangles, the neurons start to die, and then you’ve got Alzheimer’s. 

NOAM: Ok, so it’s not like an injury. It’s not an accident. 

ALEXIS: Nope. 

NOAM: It’s just something genetic.  

ALEXIS: It’s just something genetic, I mean, it’s a mutation according to his theory. 


ALEXIS: He describes this thinking, he dashes off a letter to the journal Nature with his findings, you know, kind of explains the evidence he’s found and what he thought was compelling

<TAPE> JOHN: And when I wrote the article, which is called The Amyloid Cascade Hypothesis, I wrote that over a weekend literally without thinking. We just sent it in. And to my amazement, it was accepted immediately.


NOAM: And were there other ideas besides the amyloid hypothesis floating around in the early 90s?

ALEXIS: Yeah, so there’s a couple. One is that there’s a virus or you can think of it like an infectious agent that’s actually causing Alzheimer’s. 


ALEXIS: There’s another one that says that there could be these misfolded brain proteins known as prions or another brain protein called tau. And like, that’s what causes the sticky plaques and tangles and that’s where Alzheimer’s is coming from. But the amyloid hypothesis blows up and the amyloid hypothesis is king, basically.

NOAM: So how did the amyloid hypothesis win this zero sum game and take over Alzheimer’s research?

ALEXIS: I’m going to say something that sounds a little bit flippant, but it’s not flippant.

NOAM: Ok sure

ALEXIS: It blew up because we’re human and we like easy answers. 

<TAPE> JOHN: Frankly, it was simple. It was easy to write the arguments down, in a convincing way, and it was therefore easy to sell within Pharma and within academia.

ALEXIS: It was a clear narrative, you know, it was a clear target: amyloids. If we get to the amyloids, we can do something about this. We can fix it. And so we ran with that. 

NOAM: Is that a bad thing? That, you know, it seems like scientists found what they think is the cause of the problem. They pour lots of resources into it. That seems like, you know, the beginning of a success story, right?

ALEXIS: Yeah, I mean, listen, “bad” is probably not a good descriptor, you know, it’s an, it’s an understandable thing. I’m human. I like easy answers, but there’s two sort of big problems with this. One is that we haven’t been investing in other hypotheses, and that might be fine if it weren’t for problem number two, which is that it doesn’t seem like this one completely works.


<CLIP> CNBC FAST MONEY REPORTER: Between 1998 and 2014, 123 Alzheimer’s drugs failed in clinical trials. 

ALEXIS: I mean, for 30 years we’ve been developing and testing drugs all pegged to the amyloid hypothesis. 

<CLIP> CBS ANCHOR: A promising experimental Alzheimer’s drug

BLOOMBERG HOST: An experimental Eli Lilly drug 

<CLIP> CBS MORNING NEWS ANCHOR: The drug, developed by pharmaceutical giants Pfizer and Johnson and Johnson,

<CLIP> ABC7 NEWS ANCHOR: Failed its first clinical trial… 

<CLIP> CNBC SQUAWK ON THE STREET HOST: Failing to meet end goals in a pivotal study!

ALEXIS: We’ve had some drugs that do seem like they can target the plaques,ut that doesn’t really… it doesn’t really seem to move the needle in terms of the rest of the cognitive impairment and memory loss.


<CLIP> ABC7 NEWS ANCHOR: The drug did not prove effective at slowing memory loss.. Experts say this is a big blow to a theory about the disease, that Alzheimer’s is caused at least in part by brain plaque. 

ALEXIS: So it’s not working as well as we would want it to work.  

NOAM: So scientists had this consensus that amyloid proteins were causing Alzheimers, and there were some drugs that actually did work on the amyloids. But that didn’t help Alzheimer’s patients get better. So doesn’t that mean the amyloid hypothesis might be wrong?

ALEXIS: Yeah so, back when we spoke with John Hardy, he didn’t really think it was wrong, 

<TAPE> HARDY: I don’t think it’s wrong, but I think it is oversimplified. Science is about evidence. You know, if you’re not worried about the results of the clinical trials, then you’re not a scientist. So of course, I take these failures absolutely seriously. And of course they have made me change my views.


ALEXIS: I mean, I think it’s easy to get really caught up in whether or not this hypothesis is right, but actually the point is not whether or not it’s right, it’s that we have put all our eggs in the basket of the amyloid hypothesis. And that means we’re not putting energy into looking at anything else. And that means we could be missing something important. But there are other ideas around there. It’s just because amyloid made so much sense and we really want it to work. Anything that doesn’t fit into that has been sidelined.

NOAM: So for these other hypotheses that aren’t about amyloids, what does that sidelining look like? 

ALEXIS: We talked to this, neurobiologist named Ruth Itzhaki.

<TAPE> RUTH ITZHAKI (NEUROBIOLOGIST): Professor Itzhaki and doctor, if you prefer, or just Ruth, whichever suits you. 

ALEXIS: And she was working on one of the other Alzheimer’s hypotheses, the one I told you about, the virus infection. And basically, you get an infection, like, say a common form of oral herpes, right, the thing that gives you cold sores, and that infection spreads to your central nervous system… where it leads to inflammation and Alzheimers and these sticky plaques. So Ruth is looking into this. This is her theory. And she said she would submit all these papers and she’d get rejection after rejection after rejection.  

<TAPE> RUTH: I can’t remember how many journals we tried, but we certainly tried several, all of which refused it.

ALEXIS: She would go to these conferences and they either wouldn’t allow her to speak or, you know, they’d cut her time down. You know, one conference she said she went to in 2004, she got squeezed into the schedule and she had like ten minutes <Laughs> tops.

<TAPE> RUTH: I was told it was apparently a huge battle to let them agree even to my giving a talk for 10 minutes. Which, of course, was one of many other ten minute talks and therefore attended by a relatively small number of people.

ALEXIS: Mostly, they would just relegate her to having a poster. 

<TAPE> RUTH: Which was generally ignored by the people who were, let’s say, senior and influential. 

ALEXIS: So it’s a vicious cycle. You know, you don’t get any attention, so you don’t get published. Your hypothesis doesn’t get out there. You don’t get any money. So then you have less money to explore why your hypothesis would work or not work. Right? And it just keeps going and going. 

<TAPE> RUTH: It was very upsetting, all the time. I was worried that my lab would just disappear, but the people who were working with me were all on short term grants. And if I didn’t get money to continue, they’d obviously have to leave. So that went on for years and years. 

NOAM: And do we know who was actually sidelining Ruth? Like, who was making these decisions here?

ALEXIS: Oh, man, that is a complicated question. [laugh] So, you know, you can say yes, the conference organizers gave her less time, right? But the conference organizers are also responding to a broader community of science. And those people are responding to funding and to research and to publications, people who report on it and decide which stories are the most interesting stories, which ones have legs and the general public. So, if this were as easy as kind of saying, “This one person or these one group of people made a bad decision,” it’s kind of like, when I say we, I really do mean we, like all of us.


NOAM: What does Ruth feel could have happened to the viral hypothesis that she was working on if she hadn’t been sidelined?

ALEXIS: I mean, for her, you know, if she had an opportunity to really explore this, we might find that maybe there’s, maybe Alzheimer’s works in a way that we hadn’t considered before, or we might find that, you know, she was completely wrong. And it turns out, actually, it’s not a virus infection. The point is that, you know, science is about asking questions. Right. [laughs] 

NOAM: Yeah, and I assume it’s not just Ruth who’s being sidelined. Right? I imagine, you know, you named a couple of hypotheses here from virus to tau to others. I mean, it feels I… could we have even other hypotheses if we hadn’t been so singularly focused on the amyloid hypothesis?

ALEXIS: Yeah, absolutely, and I think, you know, on our podcast, we’re looking at stories, science that happened 100 years ago, 50 years ago, you know, 500 years ago. And the one consistent truth is that, you know, we get to our best work by having lots of different hypotheses, lots of different ideas, even if that makes science really, really messy [laughs] and difficult to navigate. That’s what we need. So, if we did not sort of sideline everything else before we had deeply explored them, we would be in a different place right now, I think.


NOAM: After the break: What happens when scientific research is carried out as a zero sum game. We’ll take a look at the consequences of sidelining research for patients, their families, and the entire medical system.     

NOAM: Unexplainable. We’re back. And I’m here with Dylan Scott, healthcare reporter at Vox.  


NOAM: In the first half of the show, we were talking about this single minded focus on the amyloid hypothesis, which has sort of prevented these other ideas about how to treat Alzheimer’s from taking hold. So I guess when we’re thinking about nowadays, what are the consequences of this type of attachment to a hypothesis that hasn’t really made a lot of progress?

DYLAN: I mean, first and foremost, the record of Alzheimer’s drug development over the past few decades has been one of failure. Between 1998 and 2014, about 130 drugs went through clinical trials trying to treat Alzheimer’s disease. And almost all of them have failed. 

NOAM: But now we’ve just got this brand new Alzheimer’s drug approved right? First time in a while?

DYLAN: Yeah. This summer, the FDA approved a drug, finally the first drug in nearly 20 years for Alzheimer’s disease, called aducanumab, and it has been developed by Biogen, one of the major pharma manufacturers in the world, and they really got started testing this drug back in 2015. And what they found was there did seem to be an effect on the amyloid plaques. But in terms of cognitive functioning, patients did not really seem to be seeing a benefit. 


NOAM: So this drug has sort of just done what other amyloid drugs have done in the past, right. It does what it’s supposed to do. It removes the amyloids. But patients aren’t getting better? 

DYLAN: Yeah. it seems so clear that in March of 2019, Biogen announced, like, this drug isn’t working. We’re going to halt these trials. You know, this was another dead end in the pursuit of an Alzheimer’s treatment.

NOAM: Ok, same story, same result, right?

DYLAN: Yeah. But they came back in October of 2019 with a surprise. They said that like after some of these patients had had been allowed to finish the treatment, they went back in, they had two trials going simultaneously. And they actually found that in one of those trials, according to their read of the data, there was a subset of patients who had actually seen a cognitive benefit from the disease.  

NOAM: Ok, ok, a subset of patients?

DYLAN: A subset of patients. Exactly. And they basically found like, well, if you look at these specific patients and if we throw out a few other patients who, it turned out had a very rapid progression of Alzheimer’s disease. In other words, if we trim the data a little bit to our liking, we can show a positive effect for some patients. 

NOAM: Would it be fair to say that’s sort of like shooting the arrow into the tree and then painting the target on afterwards? 

DYLAN: I mean, yeah, it does seem like that kind of thing. You know, to put it mildly, this is a really unconventional way for data to be analyzed and it’s certainly not typical for data that’s going to be used as the foundation for the FDA to approve a drug. So what happens then is, Biogen says, well, we think we’ve shown some benefit and so we’re going to push ahead for FDA approval anyway. And so the FDA’s advisory committee for neurological therapies gets together. And they all sit down, and they look at the data, and they are almost unanimous saying that the drug doesn’t seem to be effective. 

And so you know usually, that would mean that the FDA would not approve this drug. But then this June, the FDA said in spite of this track record in the clinical trials, we are going to approve this drug for use by patients in the US.


NOAM: This is weird right? 

DYLAN: It’s… it’s not normal. This is not how things are usually done. 

NOAM: What could they have possibly been thinking? I mean, like what is your outlining all the arguments against approving this drug? Like, why would they approve it?  

DYLAN: Well, that’s a good question, and honestly, I don’t think we have a very satisfying answer to that question. You know, the FDA itself has asked an independent investigator to probe the approval of aducanumab and kind of figure out what happened, which I think speaks to how strange the circumstances of this drug’s approval really were. But I think there’s at least three things that may have motivated the FDA’s decision making. 

NOAM: What kind of things?

DYLAN: First and foremost, like there clearly is a way to splice this data and show some positive effect for some patients. Secondly, I think there is some optimism within the FDA and certainly in the Alzheimer’s advocacy community that now that we’ve had one drug approved, the hope would be that this will lead to more drug development down the road. But the third, and I think maybe the most persuasive argument in favor of the FDA approving this drug is on behalf of the patients. You know, there are people out there who just want a chance to try this drug. And, you know, we’ve seen the FDA do this with cancer drugs where they’ve approved a new treatment that in the clinical trials only shows a marginal benefit, not that different from what we’re talking about with this Alzheimer’s drug. And I think the thinking behind those decisions is: Here are people who are facing a terminal illness… what’s the harm and letting them try something that might have a benefit for them. 

NOAM: Is it really as simple as that? There must be downsides to throwing spaghetti at the wall and seeing if it sticks, right?

DYLAN: Absolutely. There are downsides to approving a drug in this way. You know I think, for starters, the most important difference between aducanumab and these cancer drugs we’re talking about is that like, with any given cancer, it’s going to be a pretty small number of patients who actually qualify for this hypothetical drug that may or may not be effective. But when we’re talking about Alzheimer’s disease and aducanumab, there are six million people in the U.S. right now who are diagnosed with Alzheimer’s disease. And we’re expecting millions more people to be diagnosed in the coming years as our population is getting older.

NOAM: Yeah

DYLAN: And so this is a drug that’s really expensive. Biogen has set a list price of 56,000 dollars a year. And on its own, it could double Medicare’s drug spending every year. And this is all for a drug that we’re not even sure whether or not it works.


DYLAN: So it’s certainly possible that we’re going to have this drug that overwhelms the US healthcare system because it costs so much and we’re just going to be giving the patients who receive it false hope because it doesn’t even work. 

NOAM: Yeah, I mean, how do we weigh the potential benefit of hope against the potential downside of false hope to millions and millions of people?

DYLAN: Well, I think it’s telling that the Alzheimer’s community itself is divided on this question. I’ve talked to people who work with patients who work with caregivers. And what they’ve heard from those folks is maybe half of them are really excited. I was listening to an episode of Today Explained recently where a patient was participating in the aducanumab trial and seemed really exhilarated about it.

<CLIP> PHIL GUTIS (ALZHEIMER’S PATIENT): I am very sympathetic to the scientific method, I am trained to believe in the science, but I guess I wish the scientists could understand that this is the first ray of hope that those of us living with Alzheimer’shave had.

DYLAN: And you’ve got other people who are actually really mad, who feel like Biogen and the drug industry are taking advantage of them and selling them false hope. And one of the people that that I spoke with was Randi Epstein, who’s a medical reporter, but also somebody who has a very direct connection to Alzheimer’s disease. And knows the toll that it takes on people.

<TAPE> RANDI EPSTEIN (REPORTER): My dad’s name was Robert VP Hutter,

 DYLAN: When she was young, her dad was really, really smart. He was a doctor.  

<TAPE> RANDI: A brilliant pathologist, a world renowned pathologist, a quiet person with a dry sense of humor.

DYLAN: He ended up, later in life, being diagnosed with Alzheimers. And he actually died a few years ago, before this new drug was available to patients. But Randi remembers her mom desperately searching for a cure or a treatment– anything that could potentially buy them more time.

<TAPE> RANDI: I think it’s really hard when you’ve been married to someone who’s your equal or been with someone or partnered and and you see their decline. How can you not try something?  

DYLAN: But she also you know, she’s a reporter. She’s somebody who has a pretty astute sense of of of medicine and good practices and medicine. And she she doesn’t buy the idea that any kind of hope is worthwhile because to her there is something predatory about putting a drug out on the market with limited evidence of its effectiveness, and then expecting people who are desperate for hope to be able to make a rational decision about it.

<TAPE> RANDI: I am actually so glad my father is not alive during this debate. I would not want to get into… I’m glad that my family does not have to debate whether he should take this drug. 


<TAPE> RANDI: I can’t imagine right now someone who has a mother, a father, a partner with Alzheimer’s. Who do they look to for advice right now? I’m not sure they can look to the FDA. I’m not sure they can look to the Alzheimer’s Association. And not everyone can pick up the phone and like, call the chair of neurology and have an in-depth discussion. People are just… I feel bad for that anxiety of what people are going through.

NOAM: You know, I think it’s easy to blame the FDA here. And obviously there are good arguments for blaming them. But it also seems, like from talking to Alexis in the first half of the show, that this seems like a problem that is bigger than the FDA, right? This seems like a problem that’s been decades in the making, that comes from the entire scientific community thinking that one hypothesis is the way to treat Alzheimer’s and then even after scientists get sign after sign after sign that it’s not working they still stick with this original hypothesis, I mean, that all just doesn’t seem like the way science is supposed to work. 

DYLAN: Well, right. I mean, my understanding of science is that it’s… it’s a process of trial and error. And, yeah, you figure out what works and what doesn’t, and then you update your assumptions accordingly. And what’s frustrating about what’s been happening with Alzheimer’s drug development and drug research is that we don’t seem to be updating our assumptions even as we get all of this evidence that a particular hypothesis isn’t necessarily panning out. And, you know, when when the conventional wisdom becomes calcified, when we become so stuck in our ways that we’re not receptive to alternative explanations or other approaches, you end up in a situation like we have now where we have a drug being approved with limited evidence and all it may be offering patients is a false sense of hope.    

BYRD: This episode was reported and produced by Rigo Hernandez, Dylan Scott, Alexis Pedrick and me, Byrd Pinkerton. It was edited by Noam Hassenfeld and Brian Resnick, with help from Meradith Hoddinott and Mandy Nguyen, who also did the fact checking. Noam wrote the music. Cristian Ayala did the mixing and sound design. Lauren Katz wrote our newsletter. And Liz Kelly Nelson is the VP of Vox Audio.

We also wanted to shout out the amazing Sharon Begley, who died earlier this year. This episode draws on her award-winning reporting on Alzheimer’s disease and the amyloid hypothesis, and we wish we could have had her on the show to talk about it.

Special thanks as well to the Science History Institute, to Russ Paulsen and Rachel Sachs, and to Randi Epstein… who wrote a great book called Aroused: The History of Hormones, and How They Control Just About Everything. 

If you want to hear more about Alzheimer’s, the Distillations podcast actually did a two part episode on the subject. And their first part is all about the effect Alzheimer’s disease has on caregivers, so it’s really worth checking out. We will link to that in our newsletter, which you can subscribe to at vox.com/unexplainable. It’s very worth it. 

If you have a minute to leave us a review or a rating, we’d love that. We’d also love to hear from you! We’re at Unexplainable at vox dot com.

Unexplainable is part of the Vox Media Podcast network. And we’ll be back in your feed… next week!

Listen to more episodes

Collage of archival and drawn images related to dye making and drug manufacturing

Dyes, Drugs, and Psychosis

The first antipsychotic was discovered through a series of mistakes, starting with—of all things—a breakthrough dye.

Headshot of woman

Pink: An Interview with Dominique Grisard

In this bonus episode, the gender studies professor discusses the popular color and its history, including ties to prison experiments.

Collage with multiple color components, man in uniform, and spectrochrome

Can Color Heal Us?

For centuries people have been fascinated by the potential healing powers of color, but is there any truth to it?


    Copy the above HTML to republish this content. We have formatted the material to follow our guidelines, which include our credit requirements. Please review our full list of guidelines for more information. By republishing this content, you agree to our republication requirements.